Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire November 05, 2025 Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital […]

Blue Gold Limited Secures $140m1 to Restart the 5.1m oz Bogoso & Prestea Mold mine, with new institutional investor committing $65m GlobeNewswire November 05, 2025 Total committed capital of US $140m for restart of Bogoso and Prestea mine secured from two separate institutional backers (US $75m Equity Line of Credit, still undrawn, and new US

Larimar Therapeutics Reports Third Quarter 2025 Financial Results GlobeNewswire November 05, 2025 In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference GlobeNewswire November 05, 2025 WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conference webcast will be

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 GlobeNewswire November 05, 2025 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,

Partner1 Recognized as a 2025 Inc. Power Partner Award Winner The annual list recognizes the leading B2B companies that have proven track records of supporting entrepreneurs and helping companies grow. GlobeNewswire November 05, 2025 NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — Partner1 is proud to announce its recognition on the Inc. Power Partner Awards.

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference GlobeNewswire November 05, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer,

Aeluma Wins 2025 LEAP Award for Advanced Materials Innovation Recognizes Groundbreaking Wafer-Scale SWIR Photodetector Platform GlobeNewswire November 05, 2025 GOLETA, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced that it

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 05, 2025 Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trialPreviously announced workforce reductions resulted in $13M annualized cost savingsSuccessful completion of two financial transactions totaling $240.3M; cash runway now extends to

Electra Reactivates Construction at Cobalt Sulfate Refinery GlobeNewswire November 05, 2025 TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company“), a leader in advancing North America's critical minerals processing, has resumed construction at its cobalt sulfate refinery following the arrangement of approximately US$82 million in